PVP Ventures Ltd — Capital/Financing Update 2024

Nov 28, 2024

November 28, 2024

To

==> picture [452 x 78] intentionally omitted <==

The BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001	National Stock Exchange of India Limited “Exchange Plaza, Bandra Kurla Complex, Bandra (E) Mumbai - 400051
Scrip Code: 517556	Symbol: PVP

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and “ ” Disclosures Requirements) Regulations, 2015 ( Listing Regulations ) – Outcome of the Board Meeting held on Thursday, November 28, 2024.

Pursuant to Regulation 30 of the SEBI Listing Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e., November 28, 2024, inter-alia have considered and approved the following business transaction;

i. The board of directors of the company have approved the proposal for acquisition of substantial shares of Biohygea Global Private Limited, a health care venture located in Chennai in order to expand its fleet in the health care sector and also in order to effect the said transaction the Share Purchase cum shareholders Agreement contained with the terms and conditions, to be entered into between the company, Biohygea Global Private Limited and other parties was also placed before the board and the same was approved. The details for the same are enclosed herewith in Annexure-I.

The meeting commenced at 02.40 P.M. IST and concluded at 02.50 P.M. IST.

Kindly take the above information on records.

For PVP Ventures Limited

Digitally signed by Mahesh D DN: c=IN, o=Personal, title=7342, pseudonym=133630927511627741UZopNT Mahesh L1IX135n, 2.5.4.20=3af56ce00d0b2ad4c6e3c26fcb934 988ca03b16b6efa77cdfaa986438be3ab99, postalCode=625517, st=Tamil Nadu, serialNumber=fa78a1229c22ec5f5ad102efc 136da39f83f65e4c800cceb685538e41a92e D 71e, cn=Mahesh D Date: 2024.11.28 15:04:40 +05'30'

D Mahesh Company Secretary & Compliance Officer Attached: As in above

==> picture [452 x 104] intentionally omitted <==

Annexure-I

==> picture [452 x 78] intentionally omitted <==

Details required to be provided while disclosing event under Regulation 30 Para A of Schedule III of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023:

S.NO	PARTICULARS	DETAILS
1	Name of the target entity, details in brief such as size, turnover etc.;	Biohygea Global Private Limited
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	The investment does not fall within the ambit of Related Party Transactions and the promoters/ promoter group/ group companies of the Company do not have any existing interest either directly/indirectly in the entity being acquired.
3	Industry to which the entity being acquired belongs;	Healthcare
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Expansion into the healthcare sector.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Nil
6	Indicative time period for completion of the acquisition;	The tentative time line to complete the acquisition is 120 days from the date of approval.
7	Consideration -whether cash consideration or share swap or any other form and details of the same;	Cash consideration.
8	Cost of acquisition and/or the price at which the shares are acquired	Rs.7-/ (Rupees Seven) crore.

==> picture [452 x 104] intentionally omitted <==

	9	Percentage of shareholding /	52 percent of post acquisition.
		control acquired and / or number
		of shares acquired
	10	Brief background about the entity	Not applicable
		acquired in terms of products/line
		of business acquired, date of
		incorporation, history of last 3
		years turnover, country in which
		the acquired entity has presence
		and any other significant
		information (in brief);